Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

ZIL reported for 6 months of 2023 by RAS accounting standards

7/27/23 ZILL

Unipro reported for 6 months of 2023 by RAS

7/27/23 UPRO

Mosenergo reported for 6 months of 2023 by RAS

7/27/23 MSNG

Honeywell International reported for 6 months of 2023

7/27/23 HON

Valero Energy reported for 6 months of 2023

7/27/23 VLO

Yandex reported for 6 months of 2023

7/27/23 YNDX

Fesco develops new logistics routes to Africa

7/27/23 FESH

Genetico has received approval for use of the Prenetics test

7/27/23 GECO

Kamchatskenergo reported for 6 months of 2023 by RAS

7/27/23 KCHE

IDGC of Urals reported for 6 months of 2023 by RAS

7/27/23 MRKU